

Supplementary table 2. Human anti-human antibody (HAHA) level and peak hu14.18K322A serum level by course and prior antibody therapy.

	Course	1	1	2	2	3	3	4	4	5	5	6	6
	Patient ID	Pre HAHA	Peak _{D16} K322A	Pre HAHA	Pre Peak K322A	Pre _{D16} HAHA	Peak _{pre} K322A	Pre HAHA	Peak _{D16} K322A	Pre _{pre} HAHA	Peak _{D16} K322A	Pre HAHA	Peak K322A
No prior 14.18 mAb													
	*2	1.22	4.2	2.26	13.9	0.65	17.4	1.34	35.5	1.31	24.7	1.25	13.7
	5	0	21.2	0.06	24.4	0.04	8.3	N/A	N/A	N/A	N/A	N/A	N/A
	6	3.01	22.5	2.36	17.4	2.74	15.4	3.07	21.5	2.83	20.8	3.12	15.4
	11	0.68	23.8	0.14	14.2	0.61	16.2	0.30	12.3	0.51	14.4	0.53	10.1
	Median	0.95	21.8	1.2	15.8	0.63	15.8	1.34	21.5	1.31	20.8	1.25	13.7
Prior dinutuximab mAb													
	4	0.14	16.7	0.15	13.8	0.08	21.7	0.05	19.6	0.47	21.1	N/A	N/A
	7	0.21	21.7	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	*9	0.18	20.6	0.44	24.5	0	29.1	0.27	33.6	0.91	15.7	0.13	17.9
	10	0	12.5	0	31.7	0	30.6	0	12.3	0	18.7	0	24.5
	12	0.04	13.5	0.17	20.1	0.27	23.7	0	31.9	0.07	40.0	0.17	15.1
	13	1.16	10.1	0.36	20.4	0.28	18.5	0.23	32.0	0.09	24.2	0.12	N/A
	Median	0.16	15.1	0.17	20.1	0.08	23.7	0.05	31.9	0.09	21.1	0.13	15.1
Prior hu14.18 K322A mAb													
	*1	1.14	25.2	1.32	18.3	1.64	17.6	2.14	2.1	1.30	16.3	2.53	20.0
	3	1.55	17.0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	8	0.80	21.6	0	3.5	0	20.4	0.40	20.9	N/A	N/A	N/A	N/A
	Median	1.14	21.6	0.66	10.9	0.82	19.0	1.27	11.5	N/A	N/A	N/A	N/A
All patients combined													
	Median	0.18	20.6	0.17	18.3	0.27	18.5	0.25	21.2	0.51	20.8	0.35	15.4
	Range	0 - 3.01	4.2-25.2	0-2.36	3.5-31.7	0-2.74	8.3-30.6	0-3.07	2.1-35.5	0-2.83	14.4-40.0	0-3.12	10.1-24.5

Patient groups sorted by prior antibody treatment. Pre HAHA - Human anti human antibody (HAHA) level measured in hu14.18K322A bridge ELISA assay prior to each course. Values represent optical density readings; peak K322A - hu14.18K322A is the serum concentration of hu14.18K322A determined in ELISA as micrograms/ml serum in sample obtained 1 hr following completion of the initial 4 hr infusion of antibody for the indicated course. * Denotes patients with an increase HAHA greater than 0.7 OD units from baseline.